Big medtech's share price bloodbath
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
The fourth quarter sell-off hurt big medtech less than big pharma
Some medtech stocks did decline in 2018, but many more increased in value.
So far so adequate for big-cap medtech
Big cap medtech disappoints – but still beats pharma.
2017 saw the stars Align for big-cap medtech
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.